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Humans infected with Rift Valley Fever Virus (RVFV) generally recover after a febrile illness;
however, a proportion of patients progress to a more severe clinical outcome such as
hemorrhagic fever or meningoencephalitis. RVFV is naturally transmitted to livestock and
humans by mosquito bites, but it is also infectious through inhalational exposure, making
it a potential bioterror weapon. To better understand the disease caused by inhalation of
RVFV, Wistar-Furth, ACI, or Lewis rats were exposed to experimental aerosols containing
virulent RVFV. Wistar-Furth rats developed a rapidly progressing lethal hepatic disease
after inhalational exposure; ACI rats were 100-fold less susceptible and developed fatal
encephalitis after infection. Lewis rats, which do not succumb to parenteral inoculation
with RVFV, developed fatal encephalitis after aerosol infection. RVFV was found in the
liver, lung, spleen, heart, kidney and brain of Wistar Furth rats that succumbed after
aerosol exposure. In contrast, RVFV was found only in the brains of ACI or Lewis rats
that succumbed after aerosol exposure. Lewis rats that survived s.c. infection were not
protected against subsequent re-challenge by aerosol exposure to the homologous virus.
This is the first side-by-side comparison of the lethality and pathogenesis of RVFV in three
rat strains after aerosol exposure and the first step toward developing a rodent model
suitable for use under the FDA Animal Rule to test potential vaccines and therapeutics for
aerosol exposure to RVFV.
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INTRODUCTION
Rift Valley Fever Virus (RVFV), a mosquito-borne member of the
Bunyaviridae family of segmented negative sense RNA viruses,
causes large explosive epidemics of severe disease in livestock
that have significant economic impact in Africa and the Arabian
Peninsula. Epizootics of RVFV are characterized by high mortal-
ity in young animals, as well as abortion rates in pregnant animals
that approach 100% (Easterday et al., 1962; Coetzer and Barnard,
1977; Coetzer and Theodoridis, 1982). As a consequence of a
large number of infected livestock, the disease overflows into the
surrounding human population, often infecting >100,000 peo-
ple during a given outbreak (Laughlin et al., 1979; Meegan et al.,
1979; Jouan et al., 1989). While RVFV is transmissible to humans
by mosquito bite, the virus also spreads rapidly by mucosal and
aerosol infection caused by humans handling infected animal car-
casses (Hoogstraal et al., 1979; Madani et al., 2003; Mohamed
et al., 2010).
Human infections with RVFV begin with a short incuba-
tion period followed by a significant fever, headache, myalgia,
anorexia, and, in some cases, nausea and vomiting (Easterday,
1965; Laughlin et al., 1979). In the majority of uncomplicated
RVFV infections, a full recovery occurs within 2 weeks (Laughlin
et al., 1979). However, a small proportion of patients (1–2%)
progress to a more severe clinical outcome which primarily
include either hemorrhagic fever with jaundice or meningoen-
cephalitis (Abdel-Wahab et al., 1978; Laughlin et al., 1979;
McIntosh et al., 1980; Madani et al., 2003). Retinitis and other
ocular manifestations can also occur. Given the large number of
humans infected during the known outbreaks, a significant num-
ber of individuals can be hospitalized. The case fatality rate for
hospitalized patients is between 10 and 20% (Laughlin et al.,
1979; McIntosh et al., 1980; Madani et al., 2003). The mecha-
nisms underlying the different human clinical outcomes are not
well-understood; however, a greater understanding of the patho-
physiologic mechanisms behind the divergent human clinical
outcomes is necessary to design effective medical countermea-
sures (MCMs) to combat RVFV. While it is thought that the
primary route of transmission of RVFV in natural outbreaks is
by mosquito vectors, RVFV can be infectious and virulent when
inhaled by humans (Francis and Magill, 1935; Smithburn et al.,
1949; Hoogstraal et al., 1979) or experimental animals (Miller
et al., 1963; Anderson et al., 1991a; Morrill and Peters, 2011).
Studies performed in the 1980s (Peters and Slone, 1982;
Anderson et al., 1987; Anderson and Peters, 1988) suggest that
infection of different inbred rat strains with the virulent ZH501
strain of RVFV results in three distinct disease patterns that may
serve as models for the disparate human clinical outcome of
RVFV infection. In these reports, Wistar-Furth (WF) rats develop
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a severe hepatic disease when inoculated subcutaneously (s.c.)
with RVFV, while August-Copenhagen-Irish (ACI) rats develop
encephalitis (Bucci et al., 1981; Peters and Anderson, 1981; Peters
and Slone, 1982; Anderson et al., 1987; Bird et al., 2007). In
contrast, s.c.-injected RVFV causes little or no mortality in the
Lewis rat strain, although the Lewis rats were viremic and devel-
oped RVFV-specific antibody responses (Peters and Slone, 1982;
Anderson et al., 1987). Anderson and colleagues showed that
Wistar-Furth rats were at least partially protected against aerosol
challenge with virulent virus by a formalin-inactivated RVFV
vaccine administered subcutaneously (Anderson et al., 1991a).
Vaccinated Wistar-Furth rats that succumbed to the disease did
not develop hepatic disease but instead developed delayed-onset
encephalitis. Little data exists on the effect of aerosol exposure to
RVFV in other strains of rat.
The overall goal of the studies reported here is to determine
whether inhalation of RVFV alters the virulence and disease
course of RVFV in Wistar-Furth, ACI, or Lewis rat strains rel-
ative to what had been reported previously for subcutaneous
inoculation (Bucci et al., 1981; Peters and Slone, 1982; Anderson
et al., 1987). For Wistar-Furth and ACI rats, aerosol infection
with RVFV resembled subcutaneous inoculation in terms of dis-
ease course and outcome, although RVFV was more lethal in ACI
rats by the aerosol route than what had previously been reported
for s.c. inoculation. Lewis rats developed fatal encephalitis after
aerosol infection with RVFV, which is different from what has
been reported for s.c. inoculation where only mild disease and
viremia were noted. This report is the first step toward develop-
ing a rodent model suitable for use under the FDA Animal Rule
(Food and Drug Administration, 2002) to test potential vaccines
and therapeutics for aerosol exposure to RVFV.
MATERIALS AND METHODS
BIOSAFETY AND REGULATORY INFORMATION
All work with live RVFV was conducted at biosafety level
(BSL)-3 in the University of Pittsburgh Regional Biocontainment
Laboratory (RBL). For respiratory protection, all personnel wore
powered air purifying respirators (PAPRs; 3M GVP-1 PAPR with
L-series bumpcap) or used a class III biological safety cabinet.
All animals were housed in individually ventilated micro-isolator
caging (Allentown, Inc., Allentown, NJ). Vesphene II se (1:128
dilution, Steris Corporation, Erie, PA) was used to disinfect all
liquid wastes and surfaces associated with the agent. All solid
wastes, used caging, and animal wastes, were steam-sterilized.
Animal carcasses were digested via alkaline hydrolysis (Peerless
Waste Solutions, Holland, MI). The University of Pittsburgh
Regional Biocontainment Laboratory is a Registered Entity with
the CDC/USDA for work with Rift Valley Fever. All animal work
described here was reviewed and approved by the University of
Pittsburgh IACUC (protocol #1005740).
VIRUS PROPAGATIONAND CULTURE
RVFV strain ZH501 was kindly provided by Barry Miller (CDC,
Ft. Collins, CO) and Stuart Nichol (CDC, Atlanta). Prior to
receipt, the virus was generated from reverse genetics plasmids
(Bird et al., 2007) containing the wild-type ZH501 sequence,
which was confirmed by sequencing. Virus was propagated on
VeroE6 cells using standard methods. For virus quantitation,
standard plaque assays were performed using an agarose over-
lay (1 × minimum essential medium, 2% FBS, 1% peni-
cillin/streptomycin, HEPES buffer, and 0.8% SeaKem agarose),
incubated for 3 days at 37◦C, and visualized using crystal violet.
For titration of tissue samples, tissue pieces were homogenized in
2× volume of DMEM + 10% FBS using an Omni tissue homog-
enizer (Omni International), followed by a standard plaque assay
on the homogenate.
ANIMAL STUDIES
Female Wistar-Furth (WF/NHsd), August Copenhagan Irish
(ACI/SegHsd), and Lewis (LEW/SsNHsd) rats (8–10 weeks old)
were obtained from Harlan Laboratories. All rats were provided
rodent food (IsoPro Rodent 3000) and water ad libitum. All
rats had implantable, programmable temperature transponders
(IPTT-300; Bio Medic Data Systems, Seaford, DE) inserted sub-
cutaneously between the shoulder blades for identification and
temperature monitoring. Probit analysis was conducted using
NCSS 97 statistical software (NCSS, Kaysville, Utah).
AEROSOL EXPOSURE OF ANIMALS
Prior to animal studies, a number of “sham” aerosol expo-
sures were conducted to determine the aerosol characteristics
of RVFV. The RVFV stock was diluted to the desired nebulizer
concentration in DMEM containing 2% FBS, antifoam, and glyc-
erol, and subsequently kept on ice until used. Rats were exposed
for 10min in a whole-body aerosol chamber to a small-particle
aerosol created by a 3-jet Collison nebulizer (BGI, Inc., Waltham,
MA) controlled by the AeroMP aerosol exposure control system
(Biaera Technologies, Hagerstown, MD). A humidification cham-
ber (Biaera Technologies) was used to increase humidification in
Table 1 | Average time to death of inbred rat strains infected with
RVFV by aerosol exposure.
Average presented # dead/total Average time to LD50 (pfu)
dose (pfu) death (days)
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FIGURE 1 | Survival of three rat strains infected with aerosolized RVFV. Survival at each presented dose is shown. (A) Wistar-Furth, (B) ACI, and (C) Lewis.
(D) Shows the probit curves for each rat strain, from which the LD50 was determined.
the exposure chamber to >60%; the chamber humidity was con-
trolled and monitored by the AeroMP system. Aerosol sampling
was done via an all-glass impinger (AGI; Ace Glass, Inc., Vineland,
NJ) operating at 6 liters per minute (lpm) which was connected
to the exposure chamber. Aerosol samples were collected in 10ml
of DMEM containing 2% FBS and antifoam. The aerosol concen-
tration of virus was determined by plaque assay on the contents of
the AGI. The concentration of virus in the aerosol was calculated
by multiplying the concentration of virus in the AGI by the vol-
ume of media in the AGI (10ml) and dividing that product by the
product of the flow of air through the AGI (6 lpm) and the dura-
tion of the exposure (10min) (Roy and Pitt, 2005). The presented
dose delivered to each rat was determined as previously described
(Reed et al., 2007). First, the minute volume of the rat was cal-
culated using Guyton’s formula which is based on the animal’s
weight (Guyton, 1947). Presented dose was then determined by
multiplying the aerosol concentration of RVFV by the duration
of the exposure and minute volume.
RESULTS
WISTAR-FURTH RATS DEVELOP HIGHLY LETHAL DISEASE AFTER
AEROSOL EXPOSURE TO RVFV
Wistar-Furth (WF) rats were exposed to aerosolized RVFV at four
different doses, ranging from less than one calculated pfu/rat up
Table 2 | Relative comparison of clinical signs in rat strains after


















+ + + + +
Ruffled fur + + + +
Hunched posture + + + +
Neurological
signs∗∗
− + + + + + +
∗Porphyrin staining occurs around the eyes/nose/mouth in response to stress or
severe illness.
∗∗Neurological signs included circling or rolling in cage, head tilt, unsteady
gait.
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to 240 pfu/rat (Table 1). The rats were monitored daily for clinical
illness, weight loss, and fever response using an implanted tem-
perature transponder. Similar to previous studies using parenteral
routes of infection and one prior report describing respiratory
infection (Peters and Slone, 1982; Anderson et al., 1987, 1991a;
Bird et al., 2007), WF rats were extremely sensitive to RVFV after
aerosol exposure (Figure 1A). The number of deaths in each dose
group and the average time to death of moribund rats is shown
in Table 1. The LD50 of aerosolized RVFV in WF rats was 2 pfu
(Table 1), as calculated using probit analysis (Figure 1D). This is
similar to the published LD50 of RVFV in WF rats after subcuta-
neous or aerosol infection (1–5 pfu) (Peters and Anderson, 1981;
Anderson et al., 1991a,b).
WF rats that succumbed to infection within the first week
exhibited minimal outward signs of infection (summarized in
Table 2). Ruffled fur was observed but minimal; some also exhib-
ited a slight hunched posture before the terminal event. Rats that
succumbed to infection lost weight relative to controls and sur-
vivors; weight loss was most striking in the rats that were exposed
to the lower doses and succumbed after day 5 post-infection
(Figure 2, red lines). Rats in the highest dose group died or were
euthanized by day 4 post-infection and lost relatively little weight
(5–7%). Some moribund WF rats had red porphyrin staining
around the eyes or nose (Figure 7). Most of the rats that suc-
cumbed to infection also had a spike in body temperature 1–2◦
above baseline that occurred within the last 12 h prior to death
(Figure 3). In some rats, the spike in body temperature was fol-
lowed by a sharp decline right before death. None of the surviving
WF rats displayed fever responses during the course of infection.
Tissues from the infected rats obtained on necropsy at the
time of death or euthanasia were analyzed for viral load by
plaque assay, and infectious virus was found widespread through-
out many tissues (Figures 4A–F). The highest levels of infectious
virus were found in the liver and spleen, but 6–7 log10 pfu were
also seen in the lung. The lung is typically not thought of as a
target tissue for RVFV, but clearly inhalation of the virus results
in high levels of virus replication even several days after expo-
sure at the time of death (Figure 4B). Between 5 and 6 log10
pfu were found in heart and kidney tissue of most but not
all rats. Despite not showing neurological impairment, most of
FIGURE 2 | Body weight of Wistar-Furth rats infected with aerosolized
RVFV. Groups of six female Wistar-Furth rats were infected with RVFV
by the aerosol route at four doses plus uninfected controls. (A) 0.4pfu/rat;
(B) 5 pfu/rat; (C) 40pfu/rat; (D) 240pfu/rat. The y-axis of each graph
displays the change in weight of individual animals relative to the
average weight of the uninfected control rats (n = 6). Rats that
succumbed to infection are shown in red; rats that survived are shown
in black.
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FIGURE 3 | Body temperature of Wistar-Furth rats infected with
aerosolized RVFV. Groups of six female Wistar-Furth rats were infected
with RVFV by the aerosol route at four doses plus uninfected controls.
(A) 0.4 pfu/rat; (B) 5pfu/rat; (C) 40pfu/rat; (D) 240 pfu/rat; (E) uninfected
control rats. The y-axis of each graph displays the change in body
temperature of individual rats relative to their temperature on the day of
infection. Rats that succumbed to infection are shown in red; rats that
survived are shown in black.
the WF rats had 3–5 log10 pfu in brain tissue. Rats that were
exposed but survived infection had no detectable virus in any tis-
sues at the time of euthanasia (22 d.p.i.; data not shown). The
presented dose that the rats received did not have a significant
correlation with the amount of infectious virus found in the
tissues.
In summary, WF rats were highly susceptible to aerosolized
RVFV. The rapidly progressing disease in this strain of rat
occurred in a similar time frame as previously published
parenteral infection, and the LD50 after aerosol was also similar
to previous publications (Anderson and Peters, 1988; Anderson
et al., 1991a; summarized in Table 3).
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ACI RATS DEVELOP NEUROLOGICAL DISEASE AFTER AEROSOL
EXPOSURE TO RVFV
Limited historical data suggested that ACI rats infected subcu-
taneously with high doses of RVFV (103–105 pfu/rat) displayed
neurological signs, and 10–50% of them succumbed to infec-
tion between 9 and 15 days post-infection (Bucci et al., 1981;
Peters and Slone, 1982). To determine if inhalation of RVFV
results in a similar disease outcome, female ACI rats were exposed
to aerosolized RVFV at presented doses ranging from less than
1 pfu/rat up to 3900 pfu/rat (Figure 1B and Table 1). ACI rats
were monitored for clinical illness, weight loss, and fever. Using
probit analysis, the LD50 of RVFV in ACI rats was 123 pfu
(Figure 1D). ACI rats infected with RVFV by aerosol at the two
highest doses (3900 and 250 pfu) died between 6 and 8 days
post-infection (Table 1). Three later deaths (day 13–14 post-
infection) were seen at the lower doses (Figure 1B).
FIGURE 4 | Continued
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FIGURE 4 | Tissue viral loads in rats infected with aerosolized RVFV. Viral loads in tissues were measured by plaque assay and are expressed as pfu/g tissue.
(A–F) show results fromWistar-Furth rats, with results grouped based on the presented dose. (G,H) show results of brain tissue from ACI and Lewis rats, respectively.
Table 3 | Comparison of disease outcome of different rat strains after subcutaneous or aerosol exposure to RVFV.
Rat strain Dose (pfu) Subcutaneous* Aerosol Comparison S.C. vs. Aerosol
Ave % Time to death Ave % Time to death
mortality (days) mortality (days)
Wistar-Furth 103 90 3 100 4 Severe hepatic disease; similar time
frame and clinical signs
ACI 103 10 15 100 6 Neurological disease; similar clinical
signs; shorter time frame and
increased lethality by aerosol
Lewis 103 0 N/A 100 7 High lethality at modest doses by
aerosol
∗Subcutaneous exposure data from Peters and Slone (1982).
Moribund ACI rats had apparent neurological signs, including
head tilt, rolling in cage, and instability (Table 2). Rats that suc-
cumbed to infection had a decrease in body weight and a 2–3◦C
temperature spike followed by a drop in temperature prior to
death/euthanasia (Figures 5 and 6). Surviving rats also did not
gain as much weight as control animals, even at the lowest dose
(Figure 5A). Several rats that survived infection also had a tran-
sient fever; however, none of the survivors displayed neurological
signs.
Porphyrin secretion by the lacrimal gland behind the eye can
be indicative of severe illness or stress. Most of the moribund
ACI rats exhibited dramatic porphyrin staining around the eyes
and/or mouth during end-stage disease prior to death/euthanasia
(Figure 7). Extensive porphyrin staining along with other clinical
parameters (neurological distress, weight loss, fever) was an
important criterion for euthanasia in all three strains of rat.
Tissues from the infected ACI rats were analyzed for viral load
by plaque assay (Figure 4G). High levels of virus (6–8 log10 pfu)
were found in brain tissue from all moribund or neurologically
distressed rats. However, virus was undetectable in all other tis-
sues tested, including blood, liver, spleen, lung, kidney, and heart
(data not shown). Rats that survived infection, including those
with a measurable spike in temperature, had no detectable virus
in any tissues at the time of euthanasia (28 d.p.i.). As was seen
with theWF rats, the presented dose that the rats received did not
have a significant correlation with the amount of infectious virus
found in brain tissue.
In review, ACI rats developed a fever and neurological dis-
ease after aerosol infection with RVFV, and the brain was the
main tissue targeted for viral replication at end-stage disease.
While the neurological signs seen in the ACI rats were similar to
what has been documented for parenteral infection (Bucci et al.,
1981), the overall lethality was increased after inhalational expo-
sure (100% vs. 10–50%, respectively, at comparable doses) and
death occurred in a shorter time frame than s.c. infection (6–8
days vs. 9–15 days, respectively; summarized in Table 3).
LEWIS RATS ALSO DEVELOP NEUROLOGICAL DISEASE AFTER
AEROSOL EXPOSURE TO RVFV
In two previously published reports, no deaths of Lewis rats
were seen after parenteral infection with up to 5 × 105 pfu of the
ZH501 strain of RVFV (Peters and Anderson, 1981; Peters and
Slone, 1982). A third study reported 17% mortality of Lewis rats
infected with 105 pfu by the s.c. route (Anderson et al., 1987).
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FIGURE 5 | Body weight of ACI rats infected with aerosolized RVFV.
Groups of six to eight female ACI rats were infected with RVFV by the
aerosol route at five doses plus uninfected controls. (A) 0.4pfu/rat;
(B) 2 pfu/rat; (C) 20pfu/rat; (D) 250pfu/rat; (E) 3900pfu/rat. The y-axis
of each graph displays the change in weight of individual animals relative
to the average weight of the uninfected control group (n = 4). Rats
that succumbed to infection are shown in red; survivors are shown
in black.
Similar to what was done with the Wistar-Furth and ACI rats
described above, female Lewis rats were exposed to aerosolized
RVFV at presented doses ranging from 1.5 to 4400 pfu (Table 1).
Unexpectedly, 8/8 rats died at a dose of 4400 pfu and 5/6 rats
died at a dose of 350 pfu, all between 6 and 9 days after infec-
tion (Figure 1C). No other deaths were observed in the lower dose
groups. By probit analysis, the LD50 was calculated to be 112 pfu
(Figure 1D and Table 1).
Similar to the ACI rats, moribund Lewis rats had neuro-
logical signs, including head tilt, rolling in cage, and insta-
bility (Table 2). Lewis rats that succumbed to infection had a
moderate decrease in body weight (8% maximum compared
to 10–20% decrease in ACI rats) and a 2–3◦C temperature
spike prior to death/euthanasia (Figures 8 and 9). Unlike what
was seen in the ACI rats, there were no dramatic temperature
spikes in Lewis rats that survived. Porphyrin staining was also
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FIGURE 6 | Body temperature of ACI rats infected with aerosolized
RVFV. Groups of six to eight female ACI rats were infected with RVFV
by the aerosol route at five doses plus uninfected controls. (A) 0.4 pfu/rat;
(B) 2pfu/rat; (C) 20pfu/rat; (D) 250pfu/rat; (E) 3900pfu/rat; (F) Uninfected
control rats. The y-axis of each graph displays the change in body
temperature of individual animals relative to their temperature on the day of
infection. Rats that succumbed to infection are shown in red; survivors are
shown in black.
seen in moribund Lewis rats, but to a lesser degree than the
ACI rats.
Tissues from the infected Lewis rats were analyzed for viral
load by plaque assay (Figure 4H). The results were similar to
those found for the ACI rats. Very high levels of virus (6–8
log10 pfu) were found in brain tissue from all moribund rats
exhibiting neurological distress. Virus was undetectable in all
other tissues. Surviving rats also had undetectable levels of virus
in tissues and blood.
Because the deaths seen here in the Lewis rats were contra-
dictory to previously published reports using s.c. infection with
RVFV strain ZH501, a cohort of five Lewis rats were infected s.c.
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FIGURE 7 | Example of porphyrin staining in ACI rats.
Chromodacryorrhea (dried porphyrin) on the eye and paw of ACI rat H1
immediately prior to euthanasia (14 d.p.i.).
with a comparable dose of RVFV (2750 pfu). All rats survived
with no clinical signs of infection, including weight loss or fever
(Figure 10, blue line), confirming that in our hands Lewis rats
are resistant to death after s.c. infection in accordance with the
previous reports.
The Lewis rats that survived the subcutaneous infection were
then re-challenged with RVFV by aerosol 28 days after the ini-
tial s.c. exposure. Of the five rats re-challenged, four of them
died with similar neurological signs and within a similar time
frame (6–7 days) as the aerosol-only Lewis rats (Figure 10A, green
line). Fever and weight loss were noted in the four re-challenged
rats (Figures 10B,C). The one rat that survived re-challenge did
not display clinical signs or fever, but did have transient weight
loss between days 13 and 15 after re-challenge. Thus, prior s.c.
infection did not provide protection of Lewis rats from aerosol
challenge with the homologous virus.
In review, Lewis rats displayed unexpected lethality after
inhalation of modest doses of RVFV (summarized in Table 3).
Fever and neurological signs were similar to that seen with ACI
rats, and brain tissue was the main target of viral replication
at end-stage disease. The reasons for the discrepancy between
s.c. and aerosol outcome of Lewis rats are currently under
investigation.
DISCUSSION
RVFV is one of many pathogens for which there is concern
because of its potential use as a biological weapon (Department of
Health and Human Services, 2005; United States Department of
Agriculture, 2005). MCMs that can protect against RVFV, partic-
ularly after aerosol exposure, are urgently needed. Because there
are insufficient numbers of confirmed human cases resulting
from aerosol exposure to RVFV, experimental studies in relevant
animal models would aid in determining whether altering the
route of infection would result in differences in the human clinical
disease. Licensure of MCMs against RVFV will require using the
Animal Efficacy Rule of the U.S. Food and Drug Administration
(FDA), which allows for a demonstration of product efficacy
in one or more well-characterized animal models which are
considered relevant to the disease in humans (Food and Drug
Administration, 2002). The FDA requires that studies done under
the Animal Efficacy Rule to support licensure of a product against
inhalational exposure must include an aerosol challenge. The goal
of the experiments reported here was to evaluate the impact of
aerosol infection upon the disease course and outcome of inhaled
RVFV in different inbred rat strains.
By fortuitous circumstance, different inbred rat strains devel-
oped different disease outcomes after s.c. inoculation with RVFV
that resemble the spectrum of human disease (Bucci et al., 1981;
Peters and Slone, 1982; Anderson et al., 1987). Of the three rat
strains, only data in Wistar-Furth rats has been reported previ-
ously for aerosol exposure. Anderson et al. (1991a) reported that
the LD50 for Wistar-Furth rats was 1 pfu by the aerosol route,
which is comparable to what has been reported for s.c. inocu-
lation (Anderson and Peters, 1988). Because it had been more
than two decades since the previous report was published describ-
ing aerosol challenge of Wistar-Furth rats, our first goal was to
determine whether there had been any appreciable change in the
lethality of ZH501 in Wistar-Furth rats. Probit analysis of the sur-
vival studies found no difference in the LD50 from prior estimates
for aerosol exposure or s.c. inoculation (Tables 1 and 3). Also in
agreement with the results from the prior studies, Wistar-Furth
rats succumbed due to a rapidly progressing severe disease, and
the time to death was similar (2–8 days).
This study represents the first known report of an LD50 of
RVFV in ACI rats by any route of infection. The LD50 in ACI rats
after aerosol exposure was 100-fold greater than that of Wistar-
Furth rats (123 pfu vs. 2 pfu, respectively), which highlights the
differences in susceptibility to severe disease exhibited by the two
inbred strains of rat. At the highest presented doses, the ACI rats
lived several days longer than the WF rats, and they displayed
significant clinical neurological signs. Aerosol exposure of ACI
rats resulted in 100% lethality at 3900 pfu within 6 d.p.i. This
is a much higher lethality and shorter survival time than previ-
ous studies with s.c. inoculation which found 10% mortality at a
dose of 103 pfu and 50% mortality at 105 pfu within 15–16 d.p.i.
(Peters and Slone, 1982). While the clinical disease did not change
with aerosol exposure reported in our study, the disease course
was shortened and the rats were more susceptible to lower doses
of virus when delivered via aerosol (Table 3).
Three previously published reports showed little (17%) to
no (0%) mortality of Lewis rats after parenteral infection with
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FIGURE 8 | Body weight of Lewis rats infected with aerosolized
RVFV. Groups of six to eight female Lewis rats were infected with
RVFV by the aerosol route at four doses plus uninfected controls.
(A) 1.5pfu/rat; (B) 30pfu/rat; (C) 350pfu/rat; (D) 4400pfu/rat. The
y-axis of each graph displays the change in weight of individual animals
relative to the average weight of the uninfected control group (n = 6).
Rats that succumbed to infection are shown in red; survivors are shown
in black.
up to 5 × 105 pfu of the ZH501 strain of RVFV (Bucci et al.,
1981; Peters and Slone, 1982; Anderson et al., 1987). In our
hands, subcutaneous infection of Lewis rats with 2750 pfu also
resulted in 100% survival with no clinical signs. However, expo-
sure of the Lewis rats to aerosol doses of 350 and 4400 pfu
resulted in 83 and 100% mortality, respectively. Clinical obser-
vations as well as virology results indicate that viral encephalitis
similar to that seen in the ACI rats was induced by aerosol
exposure of Lewis rats. It is curious why this change in clini-
cal outcome occurs with Lewis rats while encephalitis is induced
in ACI rats by either route. One possibility is that the virus
may gain access to the central nervous system through the olfac-
tory bulb during aerosol infection similar to other encephalitic
viruses (Pratt et al., 2012). In support of this hypothesis, we
also observed that Lewis rats that survived s.c. infection were
not protected against subsequent re-challenge by aerosol expo-
sure to the homologous virus. Similarly, Anderson et al. (1991a)
reported that after vaccination of Wistar-Furth rats, some died
of encephalitis instead of hepatic disease after aerosol expo-
sure. The observed lack of protection from homologous virus
by aerosol challenge may also have significant implications for
development of MCMs to protect against inhalational exposure
to RVFV. Further investigation is needed to understand these
findings.
Inbred rat strains differ genetically in a number of biochem-
ical markers (Bender et al., 1994), with more differences likely
undiscovered. The outcome of RVFV infection in rats is clearly
determined by the genetic background of the inbred rat strains,
but it was not shown to be related to either cellular suscepti-
bility to infection or to the major histocompatibility complex
(Peters and Anderson, 1981). Breeding experiments conducted by
Peters and Anderson (Peters and Anderson, 1981; Anderson et al.,
1991b) demonstrated that a dominant gene determines resistance
to the fatal liver infection after RVFV infection. However, similar
experiments crossing rats susceptible to encephalitis with resistant
rats have not been as clearly revealing, suggesting a more complex
genetic component (Peters and Anderson, 1981). Others have
shown that genetic drift of inbred rat strains at different breeding
facilities between Europe and the United States can compound the
issue (Ritter et al., 2000). Investigation into the influence of the
genetic differences between rat strains will aid in understanding
the differences in outcome we have observed.
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FIGURE 9 | Body temperature of Lewis rats infected with aerosolized
RVFV. Groups of six to eight female Lewis rats were infected with RVFV
by the aerosol route at four doses plus uninfected controls. (A) 1.5pfu/rat;
(B) 30pfu/rat; (C) 350pfu/rat; (D) 4400pfu/rat; (E) Uninfected control
rats. The y-axis of each graph displays the change in body temperature
of individual animals relative to their temperature prior to infection.
Rats that succumbed to infection are shown in red; survivors are shown
in black.
In all three strains of rat, we observed no correlation between
the dose of virus the rats received and the level of infectious
virus present in tissues at the time of necropsy. Rats of the
same strain had similar levels of virus in tissues at time of death
regardless of the input dose, even though lower presented doses
resulted in lower overall death rates and a prolonged survival
(Figures 1A–C). This suggests that it may take longer to estab-
lish infection in rats exposed to lower doses, but once established,
further dissemination and replication proceeds rather uniformly
until death of the animal. It is feasible that serial sacrifice studies
conducted at different doses may reveal differences in tissue viral
loads at earlier time points after infection.
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FIGURE 10 | Effect of infection route on survival of Lewis rats.
(A) Shows survival of Lewis rats after either subcutaneous (blue line;
n = 5) or aerosol exposure (red line; n = 6). The rats that survived s.c.
exposure were re-exposed to RVFV by aerosol infection 28 days after the
original exposure (green line; n = 5). (B,C) Change in body weight and
body temperature of Lewis rats after exposure to RVFV as outlined
in (A). The purple line shows the single rat that survived aerosol
re-challenge.
In summary, this is the first comparison of RVFV infection
in three rat strains after aerosol exposure. In two of the three
rat strains, inhalation of RVFV resulted in a disease similar to
that seen after s.c. inoculation. Inhalational exposure of Wistar-
Furth and ACI rats to RVFV can serve as a suitable model for the
severe hepatic and neurological disease seen in humans, respec-
tively. However, the data from Lewis rats suggests that aerosol
exposure may be less likely to result in the milder acute febrile
disease seen in humans after mosquito transmission. Therefore,
aerosol exposure to RVFV as a result of a biological weapon
attack may be more concerning that originally realized, partic-
ularly if parenterally administered vaccines are unable to offer
good protection from neurological disease. The mechanisms that
determine these different outcomes in humans or rats are not
well-understood. Additional characterization of the pathophys-
iological mechanisms important in disease induction is needed
before these models can be considered for potential use under
the FDA’s Animal Rule (Food and Drug Administration, 2002) for
evaluation of the efficacy of potential vaccines and therapeutics.
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